# KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

> **NCT07232602** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 55 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** MK-3120
- **DRUG:** EV
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Rescue Medication

## Key facts

- **NCT ID:** NCT07232602
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2031-07-08
- **Final completion:** 2031-07-08
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232602, "KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07232602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*